Organogenesis Inc. (ORGO)
Organogenesis Statistics
Share Statistics
Organogenesis has 126.83M shares outstanding. The number of shares has increased by -4.73% in one year.
| Shares Outstanding | 126.83M |
| Shares Change (YoY) | -4.73% |
| Shares Change (QoQ) | -5.17% |
| Owned by Institutions (%) | 47.17% |
| Shares Floating | 64.38M |
| Failed to Deliver (FTD) Shares | 138 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 10.42M, so 8.28% of the outstanding shares have been sold short.
| Short Interest | 10.42M |
| Short % of Shares Out | 8.28% |
| Short % of Float | 16.19% |
| Short Ratio (days to cover) | 17.33 |
Valuation Ratios
The PE ratio is 489.38 and the forward PE ratio is 23.73. Organogenesis's PEG ratio is -2.12.
| PE Ratio | 489.38 |
| Forward PE | 23.73 |
| PS Ratio | 0.87 |
| Forward PS | 0.9 |
| PB Ratio | 1.6 |
| P/FCF Ratio | 100.9 |
| PEG Ratio | -2.12 |
Enterprise Valuation
Organogenesis Inc. has an Enterprise Value (EV) of 551.75M.
| EV / Earnings | 640.82 |
| EV / Sales | 1.14 |
| EV / EBITDA | -430.05 |
| EV / EBIT | -430.05 |
| EV / FCF | 132.12 |
Financial Position
The company has a current ratio of 3.69, with a Debt / Equity ratio of 0.16.
| Current Ratio | 3.69 |
| Quick Ratio | 3.35 |
| Debt / Equity | 0.16 |
| Total Debt / Capitalization | 14.14 |
| Cash Flow / Debt | 0.33 |
| Interest Coverage | -0.83 |
Financial Efficiency
Return on equity (ROE) is 0% and return on capital (ROIC) is 0.13%.
| Return on Equity (ROE) | 0% |
| Return on Assets (ROA) | 0% |
| Return on Capital (ROIC) | 0.13% |
| Revenue Per Employee | $554,710.01 |
| Profits Per Employee | $990.79 |
| Employee Count | 869 |
| Asset Turnover | 0.97 |
| Inventory Turnover | 4.41 |
Taxes
| Income Tax | -3.67M |
| Effective Tax Rate | 1.31 |
Stock Price Statistics
The stock price has increased by 64.44% in the last 52 weeks. The beta is 1.66, so Organogenesis's price volatility has been higher than the market average.
| Beta | 1.66 |
| 52-Week Price Change | 64.44% |
| 50-Day Moving Average | 4.18 |
| 200-Day Moving Average | 3.32 |
| Relative Strength Index (RSI) | 49.18 |
| Average Volume (20 Days) | 1.81M |
Income Statement
In the last 12 months, Organogenesis had revenue of 482.04M and earned 861K in profits. Earnings per share was -0.05.
| Revenue | 482.04M |
| Gross Profit | 366.3M |
| Operating Income | -1.28M |
| Net Income | 861K |
| EBITDA | -1.28M |
| EBIT | -1.28M |
| Earnings Per Share (EPS) | -0.05 |
Balance Sheet
The company has 135.57M in cash and 43.31M in debt, giving a net cash position of 92.26M.
| Cash & Cash Equivalents | 135.57M |
| Total Debt | 43.31M |
| Net Cash | 92.26M |
| Retained Earnings | -40.11M |
| Total Assets | 497.89M |
| Working Capital | 208.46M |
Cash Flow
In the last 12 months, operating cash flow was 14.21M and capital expenditures -10.03M, giving a free cash flow of 4.18M.
| Operating Cash Flow | 14.21M |
| Capital Expenditures | -10.03M |
| Free Cash Flow | 4.18M |
| FCF Per Share | 0.03 |
Margins
Gross margin is 75.99%, with operating and profit margins of -0.27% and 0.18%.
| Gross Margin | 75.99% |
| Operating Margin | -0.27% |
| Pretax Margin | -0.58% |
| Profit Margin | 0.18% |
| EBITDA Margin | -0.27% |
| EBIT Margin | -0.27% |
| FCF Margin | 0.87% |
Dividends & Yields
ORGO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1.07% |
| FCF Yield | 0.71% |
Analyst Forecast
The average price target for ORGO is $5.5, which is 17.8% higher than the current price. The consensus rating is "Hold".
| Price Target | $5.5 |
| Price Target Difference | 17.8% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
Scores
| Altman Z-Score | 4.86 |
| Piotroski F-Score | 9 |